One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

Adjuvant chest wall irradiation should be omitted in most patients meeting the eligibility criteria for SUPREMO,” said Ian Kunkler, MB BChir.

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.

Updated results from the KATHERINE trial showed that adjuvant T-DM1 provided a significant improvement in overall survival and no evidence of long-term safety issues.

SAN ANTONIO — The addition of anthracyclines to adjuvant taxane-based chemotherapy improved survival for certain high-risk patients with breast cancer, according to data presented at San Antonio ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

Elinzanetant reduced vasomotor symptoms frequency and severity in women with or at high risk of HR-positive breast cancer in ...

TFPy, developed by researchers at University of Illinois at Urbana-Champaign in US, induces regression of tumours in multiple ...

A MUM has shared a shocking photo of a giant lump protruding from her breast, which doctors repeatedly dismissed a benign. But after months of being told there was nothing to worry about, Tirzah ...

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...

Natera has reported the latest data from the Phase III CALGB (Alliance)/SWOG 80702 study, indicating that Signatera, a ...